IBIO stock forecast, quote, news & analysis
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases... Show more
Why iBio, Inc. (IBIO) Stock Is Down -35% in the Last 30 Days
Key Takeaways
- IBIO shares declined roughly 35% over the trailing 30 days, falling from about $1.18 to $0.77 as of late October.
- The slide extends a longer downtrend, with the stock down approximately 45% over the last three months.
- Shares traded near a 52-week low in late October, reflecting persistent pressure on early-stage, pre-revenue biotechnology companies.
- A shareholder-approved increase in authorized shares, from 275 million to 500 million, added to dilution concerns during the period.
- Positive preclinical data for lead obesity candidate IBIO-610 were offset by financing uncertainty and a clinical timeline that remains several quarters away.
- iBio expects to begin first-in-human trials for IBIO-610 in the first half of 2027.
- For deeper analysis, explore the ticker's Price Targets, Earnings, and Forecast.
- Explore Trending AI Robots for additional data-driven market insights.
iBio, Inc. (IBIO) Company Overview and Market Position
iBio, Inc. is a San Diego-based biotechnology company that combines artificial intelligence and machine learning with antibody engineering to develop next-generation therapeutics for obesity, cardiometabolic disease, and other hard-to-treat conditions. The company's proprietary AI drug discovery platform integrates epitope steering, a human antibody library, and its StableHu AI antibody-optimizing technology to design precision antibodies against targets that have historically been difficult to drug.
The company's lead programs include IBIO-610, a long-acting Activin E antibody being developed for obesity, and IBIO-600, a long-acting myostatin antibody. All of iBio's therapeutic candidates remain in preclinical or early-stage development, and the company has yet to generate meaningful product revenue. Investors follow IBIO primarily for the potential of its AI-driven platform and its pipeline in the large and competitive obesity market, where therapies designed to preserve muscle mass while promoting fat-selective weight loss represent a key area of differentiation.
iBio, Inc. (IBIO) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, IBIO declined approximately 34.9%, moving from a closing price of $1.18 on September 30, 2026, to $0.77 on October 30, 2026. The downtrend was not linear; the stock experienced brief intraday rebounds, including a spike above $0.89 in mid-October, but selling pressure repeatedly brought shares back toward the lower end of their recent range.
The quarterly picture is more pronounced. Approximately three months earlier, the stock closed near $1.39 in late July, meaning IBIO has shed roughly 45% over the last quarter. The sustained decline pushed shares to a 52-week low in late October, underscoring how far the stock has fallen from its 52-week high of $3.82 reached earlier in the year.
What Drove IBIO Stock Price in the Last 30 Days
Several company-specific developments shaped IBIO's October price action. On October 14, 2026, iBio held its 2026 annual meeting, where shareholders approved an amendment increasing the company's authorized shares from 275 million to 500 million. The company filed the related certificate of amendment with the State of Delaware on October 16. While an authorized-share increase does not by itself issue new stock, it expands the company's capacity to raise capital through future equity offerings, which can weigh on investor sentiment for a pre-revenue biotech that relies on financing to fund its operations.
The company also reported encouraging preclinical results. On October 13, iBio highlighted data from a non-human primate study showing that IBIO-610, its Activin E antibody, preserved a greater proportion of lean mass when combined with semaglutide compared with semaglutide alone. Despite the positive data, the stock continued to trend lower, reflecting broader market caution toward early-stage biotech names and the reality that meaningful clinical catalysts remain several quarters away.
Additional corporate activity included a Schedule 13G filing by Coastlands Capital and related entities disclosing a 9.72% beneficial ownership stake, and the lowering of a 12-month price target by at least one analyst. Collectively, financing-related dilution concerns, a long clinical runway, and weak small-cap sentiment outweighed the positive preclinical update.
What Drove IBIO Stock Performance Over the Last Quarter
The quarterly decline reflects a broader narrative of a preclinical-stage company navigating a challenging financing environment. Throughout the period, iBio continued advancing its pipeline toward the clinic, with management reiterating plans to begin first-in-human trials for IBIO-610 in the first half of 2027. However, the absence of near-term revenue and the ongoing need to secure additional capital to fund research and development kept pressure on the share price.
The company's recent fiscal results, which showed minimal revenue and a significant net loss, highlight the funding requirements inherent to its business model. Against this backdrop, the authorized-share increase approved in October reinforced concerns about potential future dilution. The stock's decline over the quarter also reflects a rotation away from speculative, high-risk biotech equities as investors favored companies with nearer-term catalysts and clearer paths to profitability.
Trending AI Robots
Tickeron's Trending AI Robots page offers a curated look at AI-powered trading bots that scan thousands of tickers across the market. While Tickeron's platform features hundreds of AI trading bots, only the top-performing and most relevant strategies are highlighted in this section. Each bot operates with its own approach, timeframe, and performance metrics, allowing traders to review a range of signal-driven strategies rather than a single one-size-fits-all model. The page is designed to help users discover automated trading tools that align with their own objectives and risk tolerance. Explore Trending AI Robots to see which strategies are currently drawing attention.
IBIO Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the primary catalyst for IBIO will be progress toward the clinic. Management has guided for first-in-human trials of IBIO-610 in the first half of 2027, making the submission of an investigational new drug (IND) application and subsequent trial initiation key milestones to monitor. Additional preclinical data across the company's broader pipeline, including IBIO-600 and its partnered amylin receptor program, could also influence sentiment.
Investors should also track the company's cash position and any financing activity, given the authorized-share increase and the capital-intensive nature of preclinical development. Regulatory developments in the obesity and cardiometabolic space, competitive dynamics among GLP-1 and next-generation therapies, and broader risk appetite for small-cap biotech stocks will all factor into how IBIO trades in the coming quarters. These factors carry inherent uncertainty, and outcomes cannot be predicted with confidence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IBIO sees its Stochastic Oscillator recovers from oversold territory
On October 28, 2026, the Stochastic Oscillator for IBIO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 61 instances where the indicator left the oversold zone. In 54 of the 61 cases the stock moved higher in the following days. This puts the odds of a move higher at over 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IBIO's RSI Oscillator exited the oversold zone, 36 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on IBIO as a result. In 67 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for IBIO just turned positive on October 27, 2026. Looking at past instances where IBIO's MACD turned positive, the stock continued to rise in 32 of 39 cases over the following month. The odds of a continued upward trend are 82%.
Following a +8.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBIO advanced for three days, in 186 of 223 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
IBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for IBIO entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.554) is normal, around the industry mean (3.498). P/E Ratio (-2.308) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1250.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. IBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in the development and commercialization of vaccines and therapeutic proteins
Industry Biotechnology